Silexion Doses First Patient, Cash Falls to $4.8M
AiX — Free Expert Advisor
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Silexion Therapeutics Corp (NASDAQ: SLXN) reported third-quarter 2026 results on Nov. 13, 2026, disclosing a net loss of approximately $2.5 million and cash and cash equivalents of $4.8 million as of September 30, 2026. The clinical-stage RNA interference developer said the first patient worldwide was dosed with its lead candidate SIL204 in a Phase 2/3 trial in locally advanced pancreatic cancer on September 30, 2026, at Tel Aviv Sourasky Medical Center. Third-quarter financings raised gross proceeds of roughly $5.2 million across three transactions.
Context — why the SIL204 dosing matters now
The first-patient milestone moves SIL204 from planning into active treatment, a transition the company framed as the quarter's central event. Silexion opened the trial's first site at TASMC on July 29, 2026, after Israeli Ministry of Health approval, and dosed the first patient two months later.
The trial is a prospective, randomized, controlled, multinational, open-label study. It tests SIL204 plus standard-of-care chemotherapy against chemotherapy alone in newly diagnosed, treatment-naive patients with unresectable Stage 3 locally advanced pancreatic cancer whose tumors carry a confirmed KRAS mutation.
That population is narrow by design. Patients must be treatment-naive and KRAS-confirmed, which shapes both enrollment speed and the eventual label the company could pursue.
SIL204 uses a dual-route regimen: direct EUS-guided intratumoral delivery to the primary tumor plus subcutaneous injections intended to provide systemic exposure. The study begins with a safety run-in cohort of roughly 18 patients, then expands into a randomized cohort of about 166 patients.
Additional Israeli oncology centers and leading academic medical institutions in Germany are progressing through site activation and are expected to join in the coming months, the company said. Silexion did not disclose enrollment targets by quarter, per-site activation dates outside Israel, or the number of patients screened to date.
The financing backdrop matters because clinical-stage oncology companies fund trials from the balance sheet. Silexion's cash position fell from $6.0 million at December 31, 2025, even after raising new money during the quarter, which tells readers the burn rate is running ahead of capital formation.
Data — what the numbers show
The income statement shows divergent quarterly and year-to-date trends. Research and development expenses fell 40.9% year over year to approximately $1.3 million in Q3 2026, from $2.2 million in Q3 2025. General and administrative expenses rose 27.3% to approximately $1.4 million, from $1.1 million. Net loss narrowed 24.2% to approximately $2.5 million, from $3.3 million.
Over nine months the pattern reverses. R&D rose 28.9% to approximately $4.9 million from $3.8 million, which the company tied to the operational ramp-up for the Phase 2/3 trial. G&A rose 20.0% to approximately $4.2 million from $3.5 million. Net loss widened 17.3% to approximately $8.8 million from $7.5 million.
| Metric | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| R&D expense | ~$1.3M | ~$2.2M | -40.9% |
| G&A expense | ~$1.4M | ~$1.1M | +27.3% |
| Net loss | ~$2.5M | ~$3.3M | -24.2% |
| Cash and equivalents | $4.8M | n/a | vs $6.0M at Dec 31, 2025 |
| Shareholders' equity | $3.0M | n/a | vs $2.6M at Dec 31, 2025 |
The balance sheet carried $6.8 million in total assets against $3.9 million in total liabilities at September 30, 2026. Shareholders' equity stood at $2.968 million, up from $2.603 million at December 31, 2025, aided by a $1.568 million related-party promissory note that no longer appears as a non-current liability.
Financing during the quarter comprised an August 2026 registered public offering with gross proceeds of approximately $2.5 million, a September 2026 warrant inducement transaction at approximately $0.84 million, and at-the-market sales of approximately $1.9 million. Subsequent to quarter end, on November 10, 2026, the company effected a 1-for-24 reverse share split. The report does not disclose the offering price, warrant strike, or dilution percentages.
Analysis — what it means for markets and sectors
Silexion sits in a crowded field of KRAS-directed oncology developers, and its differentiation rests on mechanism rather than scale. The company reported in August 2026 that preclinical work showed statistically significant upregulation of FAS (CD95), an immune death receptor, and downregulation of HLA-G, an immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines.
Combined with MHC-I upregulation reported in May 2026, the company said the findings support a coordinated immune-sensitization signature across three immune pathways and four KRAS mutations: G12D, G12V, G12C and G12R. Silexion framed that as reinforcing the rationale for combining SIL204 with anti-PD-(L)1 checkpoint inhibitor therapies.
In September 2026 the company reported that SIL204 uses naturally circulating lipoproteins to enter cancer cells and silence mutant KRAS without synthetic transfection reagents or artificial carriers. That supports systemic administration, and pharmacokinetic, cellular uptake kinetics and biodistribution studies remain ongoing.
The counter-argument is timing and capital. A 166-patient randomized cohort plus an 18-patient run-in is expensive, and the company ended the quarter with $4.8 million. Without additional financing, that balance covers only a fraction of the trial the company has designed. The bear case is straightforward: dilution risk if the equity window narrows.
The bull case rests on the safety run-in reading out cleanly and German sites activating on schedule. Positioning is likely split between event-driven holders awaiting the run-in data and investors who treat the reverse split and cumulative net loss as reasons to stay away. The report gives no institutional ownership figures.
Outlook — what to watch next
Three catalysts dominate. First, additional Israeli centers and German academic institutions joining the trial, which the company said are expected in the coming months without naming sites or dates. Second, completion of the approximately 18-patient safety run-in cohort, which gates expansion into the randomized phase. Third, the ongoing pharmacokinetic and biodistribution work that underpins the systemic administration claim.
On capital, the next signal is whether the company returns to the at-the-market facility or raises again. The November 10, 2026, 1-for-24 reverse split was a listing-related action, and the report gives no post-split share count.
Readers tracking this name should watch for enrollment updates and any disclosure of cash at the next reporting date. The report names no price levels, analyst targets, or valuation metrics for SLXN, so none are offered here.
Frequently Asked Questions
What does the first patient dosed mean for Silexion stock?
It marks the shift from trial setup to active treatment, which is the point at which clinical risk becomes measurable. Silexion opened its first site at TASMC on July 29, 2026, and dosed the first patient on September 30, 2026. The trial still has to complete a roughly 18-patient safety run-in before the randomized cohort of about 166 patients begins, so the milestone is early in a multi-year sequence.
Why did Silexion's cash fall to $4.8 million despite raising money?
Cash dropped from $6.0 million at December 31, 2025, to $4.8 million at September 30, 2026, even after an August offering at roughly $2.5 million, a September warrant inducement at roughly $0.84 million, and at-the-market sales of roughly $1.9 million. The nine-month net loss of approximately $8.8 million, driven by R&D of approximately $4.9 million, consumed more than the quarter's financings brought in.
What is SIL204 and how is it administered?
SIL204 is a small interfering RNA candidate that targets mutant KRAS in solid tumors. It is given through a dual-route regimen: direct EUS-guided intratumoral delivery to the primary tumor, combined with subcutaneous injections designed to provide systemic exposure. Silexion reported in September 2026 that the compound uses naturally circulating lipoproteins to enter cancer cells, which supports the systemic route.
Bottom Line
Silexion moved SIL204 into active patient treatment, but $4.8 million in cash against a 166-patient randomized trial keeps financing risk front and center.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Trade XAUUSD on autopilot — free Expert Advisor
AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
PartnerPosition yourself for the macro moves discussed above
Start TradingSponsored
Ready to trade the markets?
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.